Regulatory FDA turns to old drugs to address new diseases, persistent medical needs BioSpaceThe FDA is looking to retool drugs with sufficient evidence to support their use in other indications, particularly those with unmet need.Read full story pharminent May 12, 2026 (Last updated: May 16, 2026) BioSpace The FDA is looking to retool drugs with sufficient evidence to support their use in other indications, particularly those with unmet need. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Novo says high-dose Wegovy can cause 28% weight lossNext: BridgeBio stands up to Pfizer in ATTR-CM as late-stage data hint at better survival Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
